This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease


Grossberg, G. T., Olin, J. T., Somogyi, M., Meng, X.


International Journal Of Clinical Practice, Volume: 65, No.: 4, Pages.: 465-471

Year of Publication



Aim: The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch.; Methods: This was a retrospective analysis of a large, international, 24-week, randomised, placebo- and active-controlled trial (IDEAL, CENA713D2320) of rivastigmine in patients with mild-to-moderate Alzheimer’s disease (AD). Patients received the 9.5 mg/24 h rivastigmine patch, the 17.4 mg/24 h rivastigmine patch, 12 mg/day rivastigmine capsules or placebo. Changes from baseline at week 24 on the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale were calculated based on the patient’s mode and last prescribed patch dose. The analysis included the 4.6 mg/24 h and 13.3 mg/24 h patch doses, for which efficacy data have not previously been reported.; Results: Significant differences (p<0.05 vs. placebo) were seen on the ADAS-cog and ADCS-ADL for all mode rivastigmine patch doses (except 4.6 mg/24 h) and all last prescribed rivastigmine patch doses (except 4.6 mg/24 h and 13.3 mg/24 h). Patients with a last prescribed/mode patch dose of 9.5 mg/24 h and 13.3 mg/24 h showed significant improvements (p<0.05 vs. placebo) on the ADCS-CGIC.; Conclusion: Rivastigmine patch doses higher than 9.5 mg/24 h may offer additional benefits. The 13.3 mg/24 h patch is worthy of further investigation.; © 2011 Blackwell Publishing Ltd.

Bibtex Citation

@article{Grossberg_2011, doi = {10.1111/j.1742-1241.2011.02641.x}, url = {}, year = 2011, month = {feb}, publisher = {Wiley-Blackwell}, volume = {65}, number = {4}, pages = {465--471}, author = {G. T. Grossberg and J. T. Olin and M. Somogyi and X. Meng}, title = {Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease}, journal = {International Journal of Clinical Practice} }


activities of daily living, administration & dosage, aged, alzheimer disease, cholinesterase inhibitors, drug therapy, female, humans, male, middle aged, neuroprotective agents, phenylcarbamates, retrospective studies, rivastigmine, transdermal patch, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime